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| INTRODUCTION
Thyroid cancer represents the most common malignancy of the endocrine system. Depending on its origin, it can be further subdivided into differentiated thyroid cancer (papillary, follicular, Hurthle cell), medullary thyroid cancer and anaplastic thyroid cancer.
1 Differentiated thyroid cancer (DTC) traces its origin from follicular thyroid cells and constitutes the vast majority of thyroid malignancies accounting for approximately 90%. 1 When promptly and appropriately treated, DTC demonstrates favourable prognosis (1.9% 10-year lymph node recurrence rate in low-risk papillary thyroid cancer) compared to other malignancies.
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Epidemiological evidence suggests a notable increase in the incidence of thyroid cancer in the past two decades. 3 Controversies over the exact cause of this trend still ensue. A considerable proportion of the reported increase is due to significant improvement in the identification of low-risk lesions (papillary lesions <1 cm). 4 In the United
States, higher incidence involves all ethnicities and races. 5 This observation has been verified in several parts of the world and explains the discrepancy between increasing incidence and steady mortality rates.
The most plausible explanation suggests that greater clinical awareness and refinement in diagnostic modalities are the main reasons behind the perceived increase. 6 Furthermore it has been debated that this trend could also reflect a true increase due to environmental factors such as increased exposure to radiation usually attributable to the widespread use of CT scans. and inability to adequately characterize follicular lesions.
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Analysis of BRAF and RAS mutations in FNA specimens has been recently employed in an attempt to further refine diagnostic accuracy, 13, 14 with the BRAF V600E mutation garnering the most attention ( Figure 1 
| THYROGLOBULIN (TG)
Thyroglobulin is produced exclusively by thyroid follicular cells and serves as a precursor of the thyroid hormones. 20 Following successful [25] [26] [27] In the largest prospective study evaluating the correlation between Tg and DTC risk, a strong correlation was noted in patients at the highest Tg quartile, suggesting that prolonged elevated levels may be considered a risk factor.
28
These observations highlight a possible role for Tg in DTC pathogenesis but specificity and sensitivity are less than optimal.
In the postoperative setting, increases in Tg levels during follow-up strongly suggest either residual or recurrent disease. A meta-analysis study in 3947 patients evaluating Tg levels prior to radioiodine ablation and after hormone withdrawal (TSH stimulation), reported a very high negative predictive value (94.2%) for the absence of disease in patients with low serum Tg levels (a threshold lower than 10 ng/mL).
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These data suggest that negative Tg levels are a strong indicator for the absence of residual or recurrent disease. assays has led to increased sensitivity. 21 TgAb are relatively common 
| THYROGLOBULIN ANTIBODIES (TGAB)
The with Graves' disease undergoing total vs subtotal thyroidectomy.
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Therefore, in principle, successful removal of all thyroid tissue should be followed by a significant decrease in antibody levels. In the majority of TgAb-positive patients, levels are expected to drop significantly after the first year.
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Research findings on the role of TgAb in the preoperative setting have been conflicting. A recent retrospective study in patients undergoing surgery found that patients with DTC were twice as likely to have antibodies prior to surgery than patients with benign disorders (16% vs 9%, respectively). 39 Interestingly, the authors classified patients with micropapillary carcinoma without lymph node involvement or extrathyroidal extension in the benign group. Upon examination, these patients had similar levels of antibody positivity as those in the benign group. This may suggest that extrathyroidal spread induces antibody production.
Unfortunately, similarly to Tg measurement, various factors have been identified that result in variations in TgAb detection. Over the past decades, the methods employed have varied with most laboratories publishing results relying on modern automated TgAb tests. 40 In comparative studies of various immunometric and radioimmune assays in DTC patients, significant interassay variability was documented.
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In addition, cut-off levels differ between different manufacturers and therefore misclassifications of positive results may occur. 35 Far from being a trivial technical issue, the difference in cut-off values can severely affect the comparison between studies and could be one of the reasons for conflicting results in the literature. Therefore, TgAb levels cannot be used as a stand-alone test in postoperative surveillance.
| THYROID-STIMULATING HORMONE (TSH)
It has been suggested that TSH may induce tumour recurrence after surgery, and this is the justification for suppressive hormone therapy postoperatively. 42 Even though this strategy has not been fully vali- 49, 50 Therefore, in certain cases, the observed association may be due to autoimmunity being the decisive factor and not TSH itself.
A large cross-sectional study, Fiore et al., 48 excluded patients with
Hashimoto's or Graves' disease and observed that patients on hormone suppressive therapy had lower TSH levels and lower likelihood of developing DTC. In a subsequent study from the same group, patients with Hashimoto's thyroiditis who were on suppressive therapy and had low TSH levels did not have an increased likelihood of cancer compared to patients with benign goiters. 50 Overall, it is highly unlikely that TSH could be employed as a tumour biomarker due to its low specificity and due to the fact that many factors influence its levels. However, the aforementioned studies raise the interesting possibility that long-term TSH-induced stimulation might be a risk factor for the development of DTC. Altogether, taking into consideration published data on sensitivity and specificity, TSHR mRNA seems an unlikely candidate to supplant standard FNA cytology in the preoperative evaluation of suspicious lesions as a stand-alone examination. There may, however, be a role for its application in the evaluation of indeterminate lesions. TSHR mRNA had a sensitivity of 76% and specificity of 96% in detecting malignancy in preoperatively diagnosed follicular lesions. 67 However, in a subsequent study from the same group of investigators, the sensitivity had a range of 33%-79% depending on the Bethesda classification of the lesions (Bethesda III-V were included). 64 The concurrent application of US in both studies drastically increased sensitivity but decreased specificity. While negative predictive values were impressive (86%- and expression has been documented in the thymus, pituitary, retroorbital tissues, heart and kidney among other organs. [70] [71] [72] It is not clear whether disorders in any of these organs can lead to detectable levels of TSHR mRNA in the bloodstream. An interesting example is Grave's orbitopathy where overexpression of TSHR in orbital fibroblasts and adipocytes is now considered a crucial step in disease pathogenesis.
| mRNA BIOMARKERS
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It is likely that measurement of circulating TSHR mRNA in this subset of patients would be a reflection of extra-thyroidal mRNA expression.
Therefore, TSHR mRNA measurement shares the same disadvantages with Tg mRNA measurement.
| MICRO-RNAS
Most of the problems described in using mRNA as a biomarker stem from its inherent instability thus making it extremely sensitive to environmental conditions. Due to this fact, research has recently started to focus on micro-RNA (miRNA), which is a small noncoding RNA molecule that mainly functions in modulating mRNA translation. 73 miRNA has been shown to be differentially expressed in healthy and malignant tissues. 74 Therefore, differences in miRNA expression could serve in cancer detection and monitoring. One important advantage of miRNA compared to mRNA is that circulating mRNA is subjected to nuclease activity in the bloodstream, whereas miRNA is protected either by binding to proteins or being enclosed in exosomes or microvesicles. 75 In addition, miRNA has been shown to be resistant to environmental conditions such as room temperature 76 and research has concluded that miRNA is readily detectable in blood samples, thus making it a potential candidate as a circulating cancer biomarker. 77 miRNA is viewed as an indicator of pathological processes and is not necessarily a direct product of the tumour itself, unlike mRNA. Even though circulating thyroid cells are assumed to be the primary source of Tg and TSHR mRNA, the same statement cannot be made for miRNAs as they are not unique for different cell types. Therefore, the exact source of miRNA detected in blood samples is not identifiable, a fact that does not necessarily negate its use as a potential biomarker.
Recently, studies have tried to identify unique miRNA signatures that could help to differentiate between benign and malignant disease and that could be applied in the postoperative follow-up. [78] [79] [80] [81] [82] [83] [84] [85] In 2012, Yu et al. 78 were the first group to demonstrate the potential of circulating miRNA in the evaluation of DTC, using a combination of sequencing studies and validation through quantitative RT-PCR. Of several potential targets, the authors identified miR-151-5p and miR-222 to be overexpressed in DTC patients both in serum and in tissue samples compared to patients with benign goiter and healthy controls. 
| OTHER NOVEL TARGETS
Recently, research has expanded in several other directions targeting various biological pathways believed to be involved in DTC pathogenesis. In the light of the gradual application of BRAF V600E detection in FNA samples, attempts have been underway to evaluate its clinical significance as a putative circulating biomarker. A recent report documented a significant correlation between increased circulating levels of BRAF V600E and the presence of the mutation in surgical pathology specimens of patients with papillary thyroid cancer, suggesting its potential use as a surrogate to biopsy or FNA specimen detection.
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A similar approach has also been employed with the use of circulating cellular-free DNA with promising results. 87 However, it is important to note that the BRAF V600E mutation is not disease specific but is also present in other malignancies such as melanoma. Thus, evaluation of BRAF V600E levels could be challenging in the study of synchronous malignancies.
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Measurement of tumour cell load is another interesting approach that has been recently adopted in the quest of circulating biomarkers. Xu et al. 
| CONCLUSIONS
Differentiated thyroid cancer has emerged as a public health concern in the past few decades due to increased incidence. Regardless of the underlying factors causing this surge, a considerable number of patients undergo several diagnostic modalities in an attempt to differentiate between benign and malignant disease. US-guided FNA remains the gold standard. However, in a considerable proportion, FNA fails to definitively discern between benign thyroid diseases and DTC exposing this subset of patients to further unnecessary diagnostic testing and surgical treatment. In the postoperative setting, measurement of circulating thyroglobulin has been employed as an effective tool in detecting disease recurrence. Unfortunately, the frequent presence of thyroglobulin antibodies is a severely limiting factor for its application.
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